Intraparenchymal nerve growth factor improves behavioral deficits while minimizing the adverse effects of intracerebroventricular delivery

Nerve growth factor (NGF) delivered via intracerebroventricular (ICV) infusion restores behavioral and biochemical deficits in animal models of cholinergic hypofunction. However, ICV infusion of NGF induces an array of adverse events including weight loss, thermal hyperalgesia, and Schwann cell hype...

Full description

Saved in:
Bibliographic Details
Published in:Neuroscience 2004, Vol.124 (4), p.743-755
Main Authors: Pizzo, D.P, Thal, L.J
Format: Article
Language:English
Subjects:
Animals
Avoidance Learning - drug effects
Basal Nucleus of Meynert - drug effects
Basal Nucleus of Meynert - pathology
Behavior, Animal - drug effects
Biological and medical sciences
Cerebral Cortex - drug effects
Cerebral Cortex - enzymology
Cerebral Cortex - pathology
choline acetyltransferase
Choline O-Acetyltransferase - metabolism
Dose-Response Relationship, Drug
Electroshock
Fundamental and applied biological sciences. Psychology
hyperalgesia
Hyperalgesia - physiopathology
Hyperplasia
Ibotenic Acid - pharmacology
Injections
Injections, Intraventricular - adverse effects
intraparenchymal NGF
Male
Maze Learning - drug effects
Medulla Oblongata - drug effects
Medulla Oblongata - pathology
Nerve Growth Factor - administration & dosage
nucleus basalis magnocellularis
Rats
Rats, Inbred F344
Schwann cell
Schwann Cells - drug effects
Schwann Cells - pathology
Spinal Cord - drug effects
Spinal Cord - pathology
Vertebrates: nervous system and sense organs
water maze
Weight Gain - drug effects
Weight Loss - drug effects
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Nerve growth factor (NGF) delivered via intracerebroventricular (ICV) infusion restores behavioral and biochemical deficits in animal models of cholinergic hypofunction. However, ICV infusion of NGF induces an array of adverse events including weight loss, thermal hyperalgesia, and Schwann cell hyperplasia. We compared ICV administration with three different doses of intraparenchymally delivered NGF with cytochrome C infusion serving as a control. The goal of the study was to determine whether direct infusion of NGF would result in a more restricted topographical distribution of NGF leading to a reduction or elimination of the adverse events while still augmenting cholinergic functioning sufficiently to restore spatial mnemonic processing. Subsequent to bilateral ibotenic acid lesions of the nucleus basalis magnocellularis (NBM), NGF was delivered into the lateral ventricle or adjacent to the NBM for 11 weeks. Ibotenic acid lesions resulted in reductions in choline acetyltransferase (ChAT) activity in the cortex. The highest and medium dose of NGF led to significant restoration in ChAT activity on par with ICV infusion. The lowest dose was ineffective in altering ChAT activity in any region assayed. Similarly, the two highest doses did not alter weight gain, but ICV-NGF led to a significant weight loss. Intraparenchymal infusion resulted in a dose-dependent attenuation of the development of thermal hyperalgesia. However, the highest dose of intraparenchymal NGF induced Schwann cell hyperplasia at the level of the medulla and upper cervical spinal cord. ICV-NGF was able to completely restore spatial learning and memory as predicted while only the highest intraparenchymal dose was able to able to restore the mnemonic deficits. These data suggest that intraparenchymal infusion of growth factors may provide a viable delivery method in clinical trials using this mode of drug delivery once an optimal dose has been established.
ISSN:0306-4522
1873-7544
DOI:10.1016/j.neuroscience.2003.12.041